Table 1 Baseline characteristics for fluticasone and placebo groups.
Patients (n = 260) | ||
|---|---|---|
Fluticasone n = 128 | Placebo n = 132 | |
Age (years) (a) | 67.6 (8.9) | 67.3 (9.0) |
Male n (%) (b) | 62 (48%) | 74 (56%) |
Exacerbation history | ||
Self-reported yearly COPD exacerbation rate | 1.93 (1.52) | 1.86 (1.57) |
Antibiotics or steroids in last year(c) | 1.59 (1.71) | 1.48 (1.77) |
Smoking Status | ||
Current smoker n (%) | 52 (40.6%) | 47 (35.6%) |
Amount smoked (pack years) | 40.0 (24.2) | 38.8 (22.3) |
Medications | ||
Duration of inhaled medications (years) | 8.7 (7.0) | 8.2 (5.6) |
Daily Prescribed Dosage of ICS(d) (mcg) | 947 (784) | 812 (531) |
On LABA medication n (%) | 45 (35.1%) | 42 (31.8%) |
Influenza vaccine in winter | 104 (81.2%) | 106 (80.3%) |
Lung Function | ||
Pre bronchodilator FEV1 (litres) | 1.22 (0.54) | 1.32 (0.54) |
Post bronchodilator FEV1 (litres) | 1.31 (0.55) | 1.40 (0.56) |
Post bronchodilator FEV1 (% predicted) | 53.2 (18.2) | 55.0 (17.1) |
Reversibility (% change in FEV1) | 8.1 (8.0) | 7.2 (6.8) |
Post bronchodilator FVC (litres) | 2.40 (0.77) | 2.56 (0.88) |
Peak expiratory flow rate (L/min) | 220 (90) | 235 (90) |
Health Related Quality of Life | ||
SGRQ Total (%) | 52.6 (20.2) | 47.2 (19.4) |
EuroQol 5D total score | 0.64 (0.29) | 0.68 (0.30) |
EuroQol 5D visual analogue scale | 60.6 (18.8) | 61.1 (20.8) |
MRC Dyspnoea Scale | ||
Scale 3 or greater (%) | 77 (60%) | 66 (50%) |
Chronic Symptom Profile (d) | ||
Shortness of Breath n (%) | 96 (75%) | 95 (72%) |
Sputum Production n (%) | 69 (54%) | 78 (59%) |
Wheeze n (%) | 60 (47%) | 59 (45%) |
Cough n (%) | 72 (56%) | 69 (53%) |